课题基金基金详情
ATF3基因对恶性胶质瘤放疗敏感性的作用及其机制
结题报告
批准号:
81872467
项目类别:
面上项目
资助金额:
57.0 万元
负责人:
束敏峰
依托单位:
学科分类:
H1821.肿瘤治疗抵抗
结题年份:
2022
批准年份:
2018
项目状态:
已结题
项目参与者:
易艳玲、刘元元、董辉、陈俊涛、仲昱衡、章梦琦、栗蕾
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
客服二维码
微信扫码咨询
中文摘要
放疗是治疗恶性胶质瘤的重要手段之一。但面临射线对胶质瘤周围正常脑组织的损伤和胶质瘤细胞对射线的抵抗两大难题。我们前期研究发现,转录因子ATF3通过调控长链非编码RNA LAT对抗去神经生长因子诱导的神经元凋亡能有效保护神经元。ATF3对胶质瘤放疗敏感性的作用及其机制则有待进一步阐明。预实验发现:抑制ATF3表达能降低胶质瘤细胞的放疗敏感性;胶质瘤细胞经照射后ATF3与LGP2蛋白表达水平呈负相关;生物信息学预测显示LGP2启动子存在ATF3结合序列。由此我们提出假说:ATF3通过直接负性转录调控LGP2来增强胶质瘤的放疗敏感性。本项目拟在细胞和动物水平检测ATF3对胶质瘤放疗敏感性的作用,运用CRISPR、CHIP和双荧光素酶报告基因等方法阐明ATF3调控胶质瘤放疗敏感性的分子机制,最终为以ATF3信号通路为靶点的恶性胶质瘤新型放疗增敏剂的研发提供理论依据和靶标。
英文摘要
Radiation therapy is one of the important therapeutic treatments against malignant glioma. However, the two major issues that need to be resolved for radiation therapy of malignant glioma are the radiation induced normal brain tissue damage and resistance of glioma cells to radiation. Previously,we found that the transcriptional factor ATF3 could effectively protect neuronal cells from apoptosis induced by deprivation of neuronal growth factor via long non-coding RNA LAT. The role and underlying mechanism of ATF3 on radiosensitivity of glioma need to be further investigated. Our pilot experiment indicates that inhibition of ATF3 can decrease radio-sensitivity of glioma cells. Further investigation showed that the protein expression level of ATF3 and LGP2 was negatively correlated in glioma cells that treated by ionizing radiation. Bioinformatics analysis shows that there is an ATF3 binding sequence within LGP2 promoter. Thus, we propose a hypothesis that ATF3 enhances the radio-sensitivity of malignant glioma via direct inhibition of LGP2 transcription. The current project is: planning to test the effect of ATF3 on radio-sensitivity of glioma cells on cellular and animal levels, respectively. We will further use Crispr, CHIP and Dual-Luciferase Reporter Assay to fully clarify the underlying mechanism of ATF3 induced radio-sensitization of gliomas. This will eventually provide a new theoretical support and target for the development of a novel glioma radio-sensitizer that targets ATF3 signal pathway.
胶质瘤放疗抵抗一直是临床难题。我们研究发现,放射线或其化学模拟剂zeocin能上调胶质瘤细胞中转录因子ATF3表达。过表达ATF3基因在细胞水平能抑制胶质瘤生长。机制研究发现:zeocin能显著抑制胶质瘤细胞总m6A水平,上调RNA m6A去甲基化酶FTO和ALKBH5,激活长链dsRNA,同时能显著上调磷酸化PKR以及下游磷酸化eIF-2a水平。生物信息学预测显示免疫检查点分子PDL1基因启动子存在 ATF3结合序列。进一步发现,过表达ATF3能显著上调PDL1 mRNA和蛋白水平,抑制ATF3能下调PDL1 mRNA和蛋白水平。本研究结果提示,放射线诱导的ATF3/PDL1信号轴的激活是放疗诱导的胶质瘤免疫逃逸和抵抗的潜在分子机制。在此基础上,我们提出:放疗联合PDL1抑制剂的组合疗法是一种潜在的对抗胶质瘤放疗耐受的新策略。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
Identification and Validation of an Immune-Associated RNA-Binding Proteins Signature to Predict Clinical Outcomes and Therapeutic Responses in Glioma Patients.
鉴定和验证免疫相关 RNA 结合蛋白特征以预测神经胶质瘤患者的临床结果和治疗反应
DOI:10.3390/cancers13071730
发表时间:2021-04-06
期刊:Cancers
影响因子:5.2
作者:Tian R;Li Y;Liu Q;Shu M
通讯作者:Shu M
METTL3/IGF2BP1/CD47 contributes to the sublethal heat treatment induced mesenchymal transition in HCC
METTL3/IGF2BP1/CD47 有助于亚致死热处理诱导的 HCC 间质转化
DOI:10.1016/j.bbrc.2021.01.085
发表时间:2021-02-12
期刊:BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
影响因子:3.1
作者:Fan, Zhuoyang;Gao, Yang;Shu, Minfeng
通讯作者:Shu, Minfeng
Circadian Regulation Patterns With Distinct Immune Landscapes in Gliomas Aid in the Development of a Risk Model to Predict Prognosis and Therapeutic Response.
神经胶质瘤中具有独特免疫景观的昼夜节律调节模式有助于开发预测预后和治疗反应的风险模型
DOI:10.3389/fimmu.2021.797450
发表时间:2021
期刊:Frontiers in immunology
影响因子:7.3
作者:Tian R;Li Y;Shu M
通讯作者:Shu M
Hypoxia blocks ferroptosis of hepatocellular carcinoma via suppression of METTL14 triggered YTHDF2-dependent silencing of SLC7A11.
缺氧通过抑制 METTL14 触发 YTHDF2 依赖性 SLC7A11 沉默来阻止肝细胞癌铁死亡
DOI:10.1111/jcmm.16957
发表时间:2021-11
期刊:Journal of cellular and molecular medicine
影响因子:5.3
作者:Fan Z;Yang G;Zhang W;Liu Q;Liu G;Liu P;Xu L;Wang J;Yan Z;Han H;Liu R;Shu M
通讯作者:Shu M
Therapeutic targeting m6A-guided miR-146a-5p signaling contributes to the melittin-induced selective suppression of bladder cancer
治疗靶向 m6A 引导的 miR-146a-5p 信号传导有助于蜂毒肽诱导的膀胱癌选择性抑制
DOI:10.1016/j.canlet.2022.215615
发表时间:2022-03-12
期刊:CANCER LETTERS
影响因子:9.7
作者:Yan, Rucheng;Dai, Weiwei;Shu, Minfeng
通讯作者:Shu, Minfeng
DNMT1基因对cAMP诱导恶性胶质瘤定向分化的作用及其机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    55万元
  • 批准年份:
    2020
  • 负责人:
    束敏峰
  • 依托单位:
国内基金
海外基金